Eir Ventures is a venture capital firm that focuses on investing in early-stage life science companies. The firm provides capital, expertise, and strategic support to innovative startups in the healthcare and biotechnology sectors, aiming to accelerate their growth and bring new medical solutions to market.

Eir Ventures aims to use a strong Nordic base and focus as a foundation to help leverage the power in current global medical research, thus being part in bringing innovative medicine to the patients.

Our team has strong roots and networks in the Nordic countries, exceptional industry networks, an international perspective and proven track records:

- Experts in life science investing, company creation, and technology/science evaluation.
- The team has been part in managing funds with more than €4 billion assets under management in aggregate, with more than 30 profitable exits.
- Deep experience-based approach to Life Science Venture Capital investing – from early stage as well as more mature opportunities.
- Investing in opportunities addressing significant unmet medical needs for new therapies, medical technology and digital health.
- Strong collaborations with universities and incubators in the Nordics.

Galecto

IO Biotech

Eir Ventures

Eir Ventures is glad to be invited to present at the International Partnering in Lifescience Society (IPLS) meeting next month in Amsterdam. Looking forward to providing our perspectives on the opportunities in the Nordic Life Science sector as well as to meeting our colleagues in The Pharmaceutical industry and in other life science venture funds.

Congratulations to our portfolio company IO Biotech on the initiation of an additional clinical study of their lead candidate drug IO102-IO103 in bladder cancer.

#immunooncology #clinicaltrials #bladdercancer

Congratulations to our partner Lene Gerlach on this well deserved recognition among top women in the Danish VC and startup ecosystem

On July 10, 2020, Eir Ventures I was launched with the announcement of the first close of our fund. Since the launch, Eir Ventures have completed investments in 17 pioneering life science companies; 5 companies have taken their development programs into clinical testing, and two companies have been listed on NASDAQ (US). We continue to develop the portfolio and look forward to the coming years in the fund. The Eir Ventures team sends the best wishes for the summer to all our colleagues and friends in the Nordic and International Life Science community.

#venturecapital #lifescience #investing #biotech #team

Eir Ventures is delighted to welcome Lovisa Backemar to our investment team. . Lovisa is a Medical Doctor and holds a PhD in clinical epidemiology from the Karolinska Institute. 

#venturecapital #lifescience #investment

Congratulations to our portfolio company IO Biotech on reaching this recruitment milestone in their phase III study patients with advanced melanoma, testing the combination of IO102-IO103 with anti-PD1 therapy.

#immunooncology #melanoma #clinicaltrials

Our partner Lene Gerlach is attending Above & Beyond Group's Advanced Leadership Program for Women June 12-14th, taking place at Financial Times HQ in London featuring inspiring speechwriter Simon Lancaster, who has been working for former UK primeministers and great business leaders.

We are glad to be part of the Synapse - Life Science Connect Biobusiness Summer School. It is a good annual tradition, and our partner Stephan Christgau will be part of a session on the key role of Venture Capital to develop healthcare innovation into medical products serving unmet need of patients. #venturecapital #healthcare #innovation

EU:EIRVENTURES

Eir Ventures

Analysis Not Available